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Introduction {#sec1}
============

Naive pluripotency is established in epiblast cells of the mouse blastocyst ([@bib2], [@bib3]). The transcription factors (TFs) *Oct4*, *Sox2*, and *Nanog* are required to establish epiblast identity and are fundamental pluripotency regulators *in vivo* and *in vitro* ([@bib8]). Following implantation, the epiblast enters a transitional phase in which cells remain uncommitted and functionally pluripotent ([@bib1], [@bib29], [@bib34]). At this point, expression of OCT4 and SOX2, but not NANOG or other naive TFs, is maintained ([@bib32]). Mouse primordial germ cells (PGCs) are induced from the pluripotent post-implantation epiblast early on embryonic day (E)6 ([@bib28]) and upregulate expression of many naive pluripotency genes following specification ([@bib16]). PGCs do not contribute to chimeras when injected into blastocysts ([@bib19]), but possess a latent capacity to reacquire pluripotency, which can be revealed *in vivo* during teratocarcinogenesis ([@bib33]) or by the derivation *in vitro* of naive pluripotent stem cell lines called embryonic germ cells ([@bib18], [@bib22], [@bib30]). Furthermore, PGC development is dependent on the expression of pluripotency TFs. Conditional deletion of either *Oct4* or *Sox2* results in PGC death ([@bib4], [@bib13]). *Nanog*-null embryonic stem cells (ESCs) exhibit broad differentiation potential, including to migratory PGCs, but contribution to germ cells at E12.5 was not observed in our previous study ([@bib6]). Induced knockdown of *Nanog* in PGCs results in significant alteration of their transcriptional program and subsequent apoptosis ([@bib36]). Induction of PGC-like cells (PGCLCs) *in vitro* is impaired in the absence of *Nanog*, whereas exogenous *Nanog* improves PGCLC yield ([@bib27]), in keeping with *in vivo* findings.

*Nanog* is essential for the specification of pluripotency *in vivo* ([@bib23], [@bib31]). However, *Nanog*-null ESCs can be maintained, albeit with a reduced self-renewal efficiency ([@bib6]). The orphan nuclear receptor Esrrb is a regulator of ESC self-renewal ([@bib7], [@bib12], [@bib21]) and influences PGC numbers *in vivo* ([@bib24]). *Esrrb* is also a direct NANOG target ([@bib7]). Deletion of *Esrrb* abolishes the ability of NANOG to confer leukemia inhibitory factor (LIF) independence in ESCs ([@bib7]). Furthermore, ESRRB can compensate for NANOG function in epiblast stem cell (EpiSC) reprogramming and in induced pluripotent stem cell (iPSC) generation ([@bib7]). Thus, Esrrb is a key downstream mediator of Nanog function in the maintenance and establishment of pluripotency *in vitro*. Here, we reassess the requirement for Nanog in PGCs and investigate whether ESRRB can compensate for NANOG function during PGC development.

Results {#sec2}
=======

Conditional Deletion of Nanog Reduces PGC Numbers {#sec2.1}
-------------------------------------------------

To assess whether Nanog is required cell autonomously in PGCs, a conditional knockout strategy was used. Mice homozygous for a *Nanog* conditional allele (*Nanog*^*flox/flox*^) ([@bib6]) were crossed with *Nanog* heterozygous mice (*Nanog*^*+/−*^) ([@bib23]) harboring the *Prdm1-Cre-BAC* transgene ([@bib28]) ([Figure 1](#fig1){ref-type="fig"}A). One in four offspring carried the *Nanog* null (−) and conditionally deleted (Δ) alleles in PGCs. As Prdm1-Cre-mediated excision has been reported to be incomplete until after E10.5 ([@bib4], [@bib14]), genital ridges in control and mutant embryos were dissected at E11.5 and analyzed by immunofluorescence. NANOG protein was not detected in mutant genital ridges ([Figure 1](#fig1){ref-type="fig"}B). However, GFP-positive cells were present, indicating successful deletion of *Nanog* ([Figure 1](#fig1){ref-type="fig"}B). GFP-positive cells were positive for DAZL, indicating that these represent *Nanog*-null PGCs ([Figure 1](#fig1){ref-type="fig"}B). Compared with littermate controls, PGC numbers in *Nanog* mutant embryos were reduced 80% ([Figure 1](#fig1){ref-type="fig"}B and 1C). Surprisingly, a small number of GFP-positive mutant PGCs expressing MVH were also detected at E12.5 ([Figure 1](#fig1){ref-type="fig"}D). To establish whether these surviving *Nanog* mutant PGCs were developmentally competent, subsequent litters were allowed to go to term, and adult mutant mice of both sexes were test-crossed ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B). Male and female mutant mice were fertile ([Figure 1](#fig1){ref-type="fig"}E), passing either the knockout or conditionally deleted allele to their offspring ([Figure S1](#mmc1){ref-type="supplementary-material"}C). These findings indicate that Prdm1-Cre-mediated deletion of *Nanog* reduces the PGC number, but suggest that *Nanog* might not be strictly required for germline development.Figure 1Conditional Deletion of *Nanog* Reduces PGC Numbers(A) Strategy for *Nanog* conditional knockout. *Nanog*^*flox/flox*^ females are crossed with *Nanog*^*+/−*^*; Prdm1-Cre* male mice. As *Prdm1-Cre* is heterozygous, one in four embryos will have germline deletion of *Nanog* (*Nanog*^*Δ/−*^).(B) E11.5 genital ridge sections from *Nanog*^*Δ/−*^ and control embryos immunostained for Nanog, Dazl, and GFP and counterstained with 4\',6-diamidino-2-phenylindole (DAPI) (scale bar, 50 μm).(C) Cell counts of PGCs in *Nanog*^*Δ/−*^ and control genital ridges at E11.5. PGCs identified by co-staining for Oct4 and either Dazl or Mvh. The mean (± SD) of two biological and technical replicates for each sample are shown. ^∗^p \< 0.05 (unpaired Student's t test).(D) E12.5 genital ridges from *Nanog*^*Δ/−*^ and control embryos immunostained for GFP and Mvh and counterstained with DAPI (scale bar, 50 μm).(E) Table of breeding data for adult *Nanog*^*Δ/−*^ mice. Both male (row 2) and female (row 4 and 5) *Nanog*^*Δ/−*^ mice are fertile.See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

Nanog Is Not Essential for Germline Development {#sec2.2}
-----------------------------------------------

The requirement for Nanog in germline development was next assessed using an alternative approach. First, *Nanog*^*flox/−*^ ESC lines were derived from *Nanog*^*flox/flox*^ × *Nanog*^*+/−*^ intercrosses ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B). Two independent clones were expanded and exhibited normal ESC morphology ([Figure S2](#mmc1){ref-type="supplementary-material"}C). Both lines gave high contribution chimeras and germline transmission ([Figures S2](#mmc1){ref-type="supplementary-material"}D and S2E). Next, both *Nanog*^*flox/−*^ ESC lines were transiently transfected with Cre, and single GFP-positive cells that had deleted *Nanog* were isolated ([Figure 2](#fig2){ref-type="fig"}A). Two GFP-positive clones derived from each parental line were expanded ([Figure 2](#fig2){ref-type="fig"}B). All four *Nanog*^*Δ/−*^ clones showed a higher differentiation propensity than parental lines ([Figure 2](#fig2){ref-type="fig"}B), consistent with abrogated Nanog function. Successful recombination was confirmed by genomic PCR ([Figure S3](#mmc1){ref-type="supplementary-material"}A). Nanog was undetectable by quantitative real-time PCR ([Figure S3](#mmc1){ref-type="supplementary-material"}B) or immunostaining ([Figure 2](#fig2){ref-type="fig"}C). *Nanog*^*Δ/−*^ lines were injected into C57BL/6 blastocysts and three out of four clones produced high contribution coat color chimeras ([Figure 2](#fig2){ref-type="fig"}D and 2E). On test crossing, chimeras generated with two independent clones (derived from different parental lines) produced agouti pups, indicating successful germline transmission. This was confirmed by detection of either the null or the deleted band in agouti offspring ([Figures 2](#fig2){ref-type="fig"}E and [S3](#mmc1){ref-type="supplementary-material"}D) and detection of GFP fluorescence from the recombined allele in inner cell masses (ICMs) from a further test cross ([Figure S3](#mmc1){ref-type="supplementary-material"}C). These results demonstrate clearly that *Nanog* function is not absolutely required for germline development.Figure 2Contribution of *Nanog*-Null ESCs to Adult Chimeras, Including the Germline(A) Strategy for generation *Nanog*^*Δ/−*^ (*Nanog*-null) clonal ESC lines.(B) Phase contrast and fluorescence images of parental and *Nanog*-null ESC lines (scale bar, 100 μm).(C) Oct4, Nanog, and GFP immunostaining of parental and *Nanog*-null ESC lines (scale bar, 100 μm).(D) Chimeras generated from *Nanog*-null ESCs, C57BL/6 mates, and agouti and black pups. High-contribution chimeras generated by injection of agouti *Nanog*-null ESCs into C57BL/6 blastocysts.(E) Summary of blastocyst injections and germline contribution of four clonal *Nanog*-null ESC lines.See also [Figures S2](#mmc1){ref-type="supplementary-material"} and [S3](#mmc1){ref-type="supplementary-material"}.

Esrrb Can Compensate for Nanog Loss in PGCLCs *In Vitro* {#sec2.3}
--------------------------------------------------------

Early PGC development can be recapitulated *in vitro* by the induction of PGCLCs ([Figure S4](#mmc1){ref-type="supplementary-material"}A) ([@bib11]). Naive ESCs in 2 inhibitors (2i)/LIF acquire competence for PGCLC induction after 2 days of culture in basic fibroblast growth factor (bFGF), Activin A, and knockout serum replacement (KSR) ([Figures S4](#mmc1){ref-type="supplementary-material"}A, SD, and SE). Expression of *Prdm1* (also known as *Blimp1*) and *Prdm14,* accompanied by elevated levels of both *Nanog* and *Esrrb* ([Figure S4](#mmc1){ref-type="supplementary-material"}E) indicates PGCLC induction. In keeping with recently published data ([@bib27]), *Nanog*-null ESCs produced fewer PGCLCs than wild-type controls, as measured by a decrease in CD61^+^/SSEA-1^+^ cells after day 4 ([Figure 3](#fig3){ref-type="fig"}A). Next, the doxycycline (Dox)-inducible system for gene expression in *Nanog*-null cells ([@bib7]) was assessed for its ability to drive inducible transgene expression during PGCLC differentiation ([Figure S4](#mmc1){ref-type="supplementary-material"}B). The addition of Dox on day 2 allowed robust expression of a tdTomato transgene ([Figure S4](#mmc1){ref-type="supplementary-material"}C) without affecting PGCLC induction efficiency in either wild-type or *Nanog* mutant ESCs ([Figures 3](#fig3){ref-type="fig"}A and [S4](#mmc1){ref-type="supplementary-material"}D). The same strategy induced expression of *Nanog* ([Figures 3](#fig3){ref-type="fig"}B and [S5](#mmc1){ref-type="supplementary-material"}A) and rescued the deficit in PGCLCs on day 6 and 8 to wild-type levels ([Figures 3](#fig3){ref-type="fig"}A and 3B). ESRRB is a downstream mediator of NANOG function in ESCs and during reprogramming ([@bib7]). Deletion of *Esrrb* also reduces PGC numbers *in vivo* ([@bib24]). Interestingly, therefore, Esrrb mRNA was detectable in E14Tg2a and *Nanog*^−/−^ cells at day 2 of PGCLC differentiation ([Figure S5](#mmc1){ref-type="supplementary-material"}B). This expression increased during subsequent days of differentiation in wild-type but not *Nanog*^−/−^ cells ([Figure S5](#mmc1){ref-type="supplementary-material"}B). However, induction of Nanog restored the increasing Esrrb mRNA levels during PGCLC differentiation of *Nanog*^−/−^ cells ([Figure S5](#mmc1){ref-type="supplementary-material"}B). These observations raise the hypothesis that ESRRB might also substitute for NANOG in PGCLCs. Using the same strategy, induced expression of *Esrrb* ([Figure S5](#mmc1){ref-type="supplementary-material"}C) also rescues the CD61/SSEA1 expression deficit to an equivalent degree to Nanog ([Figures 3](#fig3){ref-type="fig"}A and 3C). PGCLCs rescued by either *Nanog* or *Esrrb* also express both Prdm1 and Prdm14, confirming their identity ([Figure 3](#fig3){ref-type="fig"}D). Compared with wild-type, *Nanog*^−/−^ PGCLCs showed an increased proportion of active caspase-3-positive cells, indicative of apoptosis ([Figure S6](#mmc1){ref-type="supplementary-material"}A). This was restored toward wild-type levels by induction of either Nanog or Esrrb ([Figure S6](#mmc1){ref-type="supplementary-material"}A). Induction of either Nanog or Esrrb also increased the staining by anti-phospho-H3, suggestive of increased proliferation ([Figure S6](#mmc1){ref-type="supplementary-material"}B). These results indicate that *Esrrb* can efficiently rescue the deficit in PGCLC differentiation observed in *Nanog* null ESCs.Figure 3Esrrb Can Replace the Nanog Requirement for Efficient PGCLC Differentiation(A) The proportion of SSEA1^+^/CD61^+^ cells during PGC differentiation of E14TG2A and ΔN-itdT (left) or ΔN-iNanog (ΔN-iN) and ΔN-iEsrrb (ΔN-iE) (right) ESCs are shown at the indicated days of PGCLC differentiation in the absence (−) or presence (+) of Dox addition from day 2 onward (please refer to [Figure S5](#mmc1){ref-type="supplementary-material"}A for differentiation protocol details). Values are means ± SDs; n = 3 biological replicates.(B and C) PGCLC differentiation of ΔN-iN (B) and ΔN-iE (C) ESCs in the presence (+) or absence (−) of Dox. The morphology and Nanog:GFP expression of aggregates are shown (left; scale bar, 200 μm) with SSEA1/CD61 analysis by fluorescence-activated cell sorting (FACS) (right).(D) Quantitative mRNA expression analysis during PGC differentiation of ΔN-iN (left) and ΔN-iE (right) in the presence (+) or absence (−) of Dox at the indicated number of days of PGCLC differentiation. Values are means ± SDs; n = 3 biological replicates. ^∗^p \< 0.05; ^∗∗^p \< 0.01; and ^∗∗∗^p \< 0.001 (unpaired Student's t test).See also [Figures S4--S6](#mmc1){ref-type="supplementary-material"}.

Esrrb Can Compensate for Nanog Loss in PGCs *In Vivo* {#sec2.4}
-----------------------------------------------------

Having established that Esrrb can compensate for Nanog loss in PGCLCs, we next devised a strategy to assess whether Esrrb might compensate for Nanog loss in PGCs *in vivo*. First, ESCs were generated by homologous recombination, in which *Esrrb* cDNA was expressed from the endogenous *Nanog* locus at the Nanog AUG start codon (designated *Esrrb* knockin \[KI\]) ([Figure S7](#mmc1){ref-type="supplementary-material"}A). Correctly targeted *Nanog*^*+/EsrrbKI*^ ESCs were identified ([Figure S7](#mmc1){ref-type="supplementary-material"}B). To assess Esrrb mRNA expression in the Esrrb knockin model, we analyzed *Nanog*^−/−^ ESCs carrying this Esrrb knockin allele. This showed that *Nanog*^−/−^ ESCs express Esrrb mRNA at ∼60% of the wild-type level and that *Nanog*^*−/EsrrbKI*^ ESCs express Esrrb mRNA at ∼2-fold the level of wild-type ESCs ([Figure S7](#mmc1){ref-type="supplementary-material"}C). *Nanog*^*+/EsrrbKI*^ ESCs were used to establish mouse lines by injection into blastocysts. *Nanog*^*+/EsrrbKI*^ mice were viable and fertile, with no obvious developmental defects (unpublished data). The *Prdm1-Cre-BAC* transgene was then introduced and resulting mice crossed with the *Nanog*^*flox/flox*^ females ([Figure 4](#fig4){ref-type="fig"}A). In this case, one in four offspring would carry both an *EssrbKI* and a *Nanog* conditional (*flox*) allele in combination with a *Prdm1-Cre-BAC* transgene ([Figure S8](#mmc1){ref-type="supplementary-material"}A). This combination, which is anticipated to result in *Nanog*^*Δ/EsrrbKI*^ PGCs, was identified by genotyping somatic tissue ([Figure S8](#mmc1){ref-type="supplementary-material"}B). Immunofluorescence of genital ridges from E12.5 *Nanog*^*Δ/EsrrbKI*^ embryos revealed equivalent numbers of DAZL-positive PGCs compared with littermate controls ([Figures 4](#fig4){ref-type="fig"}B and 4C). NANOG protein could not be detected in *Nanog*^*Δ/EsrrbKI*^ PGCs, which were instead immunoreactive for GFP ([Figure 4](#fig4){ref-type="fig"}B). These results indicate that expression of *Esrrb* under the control of *Nanog* regulatory elements can rescue development of *Nanog*-null PGCs. Furthermore, *Nanog*^*Δ/EsrrbKI*^ PGCs are fully competent to complete germline development, as both male and female of this genotype were fertile ([Figures 4](#fig4){ref-type="fig"}D and [S8](#mmc1){ref-type="supplementary-material"}C). Taken together, these observations both *in vitro* and *in vivo* suggest that Esrrb can substitute for Nanog function in germ cells.Figure 4Esrrb Expression Can Rescue Development of *Nanog*^−/−^ PGCs(A) Schematic of *Nanog* conditional knockout, Esrrb knockin strategy. *Nanog*^*flox/flox*^ female mice are crossed with *Prdm1-Cre*: *Nanog*^*+/EsrrbKI*^ male mice. As *Prdm1-Cre* is heterozygous, one in four offspring will be *Nanog* conditional knockout, Esrrb knockin (*Nanog*^*Δ/EsrrbKI*^).(B) E12.5 genital ridges from *Nanog*^*Δ/EsrrbKI*^ and control embryos. GFP expression is from the conditionally deleted (*Δ*) allele and is specific to germ cells of the genital ridge (scale bar, 50 μm).(C) Cell numbers were counted from *Nanog*^*Δ/EsrrbKI*^ and control genital ridges. PGCs are identified by Dazl expression. The mean (± SD) of three biological replicates for control and *Nanog*^*Δ/EsrrbKI*^ are shown. n.s., not significant.(D) Table of breeding data for adult *Nanog*^*Δ/EsrrbKI*^ and control mice. Both male (row 3) and female (row 4) *Nanog*^*Δ/EsrrbKI*^ mice are fertile.See also [Figures S7](#mmc1){ref-type="supplementary-material"} and [S8](#mmc1){ref-type="supplementary-material"}.

Discussion {#sec3}
==========

Although conditional knockout approaches have shown that the Oct4 and Sox2 are essential for PGC development ([@bib4], [@bib13]), studies on other pluripotency TFs have proved challenging. Here, we use conditional knockout strategies, mouse chimeras, and the recently developed PGCLC system ([@bib11]) to assess the function of the Nanog-Esrrb axis in PGCs. This study establishes a role for Nanog in regulating PGC numbers *in vivo*. However, as for ESCs ([@bib6]), Nanog is strictly dispensable for PGC function. We show that knockin of *Esrrb* to the *Nanog* locus can complement the Nanog defect and is sufficient to rescue PGC numbers *in vivo*. Our study also supports a recently proposed role for Nanog in the maintenance of PGCLCs from pluripotent stem cells *in vitro* ([@bib27]), but expands on these findings, establishing that Esrrb can substitute for Nanog function in this system. Therefore, in addition to ESC self-renewal and iPSC reprogramming, Esrrb can functionally substitute for Nanog in PGC development. This strengthens the hypothesis that aspects of the naive pluripotency network are re-established in PGCs ([@bib17]). It will therefore be interesting to see whether the recently reported mitotic bookmarking activity of Esrrb in ESCs is also conserved in PGCs ([@bib9]).

Previous experiments have suggested that Nanog is required for PGC development ([@bib6], [@bib36]). Although chimera experiments showed that *Nanog*^*−/−*^ ESCs could form nascent PGCs at E11.5, *Nanog*-null PGCs were not observed one day later at E12.5 ([@bib6]). This loss of PGCs was shown to be due to *Nanog* mutation, since repair of *Nanog* by homologous recombination restored E12.5 PGCs ([@bib6]). These findings were largely supported by a study in which induced knockdown of Nanog led to PGC death ([@bib36]). More recently, however, *Nanog*^*−/−*^ iPSCs were reported to be capable of germline transmission based on expression of a GFP transgene in tissues of chimera-derived offspring ([@bib5]). Our present findings provide unequivocal evidence that PGC development can be completed in the absence of Nanog by showing that two newly derived *Nanog*^*−/−*^ ESC lines exhibit germline transmission, as judged by coat color and the presence of *Nanog*-null alleles in F1 pups. Together with the severe reduction in PGC numbers observed in our conditional deletion experiments, this clarifies that the absence of NANOG compromises the development of the PGC population, but that individual PGCs can acquire full functionality in the absence of NANOG. This germline phenotype may render *Nanog*^*−/−*^ PGCs disadvantaged compared with wild-type PGCs in the context of chimeras and reduce the frequency with which germline competency is observed. Our previous *Nanog*-null chimera experiments were performed using ESCs cultured in LIF/fetal calf serum (FCS). In contrast, both current examples of germline transmission were obtained using cells cultured in 2i/LIF, which may have enhanced the degree of chimerism, thereby increasing the likelihood of observing germline transmission, as previously shown for 3i/LIF culture medium ([@bib15]).

The fact that Esrrb can substitute for Nanog provides functional evidence that the naive pluripotency network may be conserved in PGCs. It is of interest that Esrrb fully restored PGC numbers by E12.5 when expressed from *Nanog*. Tetraploid embryos complemented by morula aggregation with *Esrrb*-null ESCs showed a reduction in PGC numbers of 50%--80% between E13.5 and E15.5 ([@bib24]). Esrrb transcripts were first detected by real-time (RT)-PCR at E11.5 ([@bib24]), with Nanog expression detected earlier in PGCs ([@bib35]). However, re-analysis of published single-cell RNA sequencing (RNA-seq) data from PGCs ([@bib10], [@bib20]) shows that Esrrb and Nanog mRNAs both increase in expression from E6.5 to E7.5, remaining relatively steady thereafter until E12.5 ([Figure S9](#mmc1){ref-type="supplementary-material"}). This suggests that ESRRB may function in PGCs before E11.5. Esrrb is also expressed during PGCLC differentiation, but at a reduced level in *Nanog*^−/−^ PGCLCs relative to wild-type cells. The wild-type expression level of Esrrb mRNA is restored in *Nanog*^−/−^ PGCLCs by Nanog induction. These results indicate that NANOG controls *Esrrb* expression in PGCs, but that, as is the case in ESCs, positive inputs in addition to NANOG also contribute to *Esrrb* expression ([@bib7], [@bib21]).

*Nanog*^−/−^ cells undergoing PGCLC differentiation showed increased apoptosis and reduced proliferation, validating previous important observations using an *in vivo* conditional knockdown approach ([@bib36]). Consistent with this seminal study, apoptotic cells positive for active caspase-3 were invariably either OCT4 low or OCT4 negative. Restoring either Nanog or Esrrb expression in *Nanog*^−/−^ PGCLCs is sufficient to reverse both the apoptosis and proliferation defects. Together, these studies add to the evidence that Esrrb is a physiologically relevant mediator of PGCLC function ([@bib24]).

A limited number of studies have focused on other naive pluripotency factors in the germline. In addition to Oct4 and Sox2, conditional knockout of *Sall4* in PGCs does appear to affect gonadal PGC numbers, although interpretation is complicated by the mosaic deletion brought about by TNAP-Cre ([@bib37]). The extent to which other pluripotency factors influence germline competence, PGC specification, and subsequent development is of significant interest. The PGCLC system may be an ideal tool to assess these factors. Recently, it was reported that induced expression of Nanog is sufficient to induce PGCLCs from epiblast-like cells (EpiLCs) ([@bib27]). Together with our data, this may indicate that Nanog has a dose-dependent influence on both the specification and maintenance of PGCs. This is reminiscent of the role of Nanog in ESCs, in which Nanog is not absolutely required, but functions as a pluripotency rheostat ([@bib6], [@bib26], [@bib25]). In this regard, it is notable that *Prdm14* is a direct Nanog responsive gene in ESCs ([@bib7], [@bib8]) and responds to Nanog in EpiLCs ([@bib27]). The ability of Esrrb to restore function *in vitro* to *Nanog*^−/−^ PGCLCs further underscores the similarities between naive pluripotency and germline development. It would be interesting to assess whether elevated levels of Nanog or Esrrb *in vivo* might enhance PGC specification and germ cell numbers. How such manipulations of the pluripotency gene regulatory network might affect PGC identity is also of interest. This will enable us to reveal how the pluripotency gene regulatory network interacts with germ-cell-specific genes during PGC development and so build on the remarkably insightful studies that first pioneered the connection between pluripotency and the germline more than half a century ago ([@bib33]).

Experimental Procedures {#sec4}
=======================

Animal studies were authorized by a UK Home Office Project License and carried out in a Home-Office-designated facility.

PGCLC Differentiation {#sec4.1}
---------------------

PGCLC differentiation was performed essentially as described previously ([@bib11]). Briefly, ESCs were cultured in 2i/LIF medium (as above) for several passages. Cells were then seeded onto fibronectin-coated plates at 1 × 10^5^ cells/12 well in N2B27/1%KSR/bFGF/Activin A to obtain EpiLCs. Two days later, EpiLCs were collected and aggregated at 2,000 cells/well in PGCLC medium (50 ng/mL bone morphogenetic protein (BMP)4, 50 ng/mL BMP8a, 10 ng/mL stem cell factor \[SCF\], 10 ng/mL epidermal growth factor \[EGF\], and 1,000 U/mL LIF) using U-bottom 96-well plates (Thermo Fisher Scientific, 174925). For induction of gene expression, 1 μg/mL Dox (Sigma, D9891) was added at day 2 of PGCLC differentiation.

Further methods can be found in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.
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